research Diphenylcyclopropenone Treatment Outcomes for Alopecia Areata
Diphenylcyclopropenone is effective for treating alopecia areata but has a high relapse rate.
Search
for
Sort by
Research
330-360 / 1000+ results 
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Administration of finasteride modulates depressive-like behavior in the forced swim task of male rats
research Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists
New compounds were made that are promising for prostate cancer therapy.
research Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin
DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research UNITY INOVA NMR Spectrometer Systems Installation Planning
Divalproex sodium significantly improved headaches in two-thirds of patients.
research 11 Treatment of hirsutism and acne with cyproterone acetate
Cyproterone acetate is effective for treating hirsutism and acne but less so for hair loss, with side effects similar to birth control pills.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research The AhR pathway is dysregulated in alopecia areata
Targeting the AhR pathway may help treat alopecia areata.
research END OF LIFE CARE IN INPATIENT PSYCHIATRY: A CASE STUDY ON END-STAGE ALZHEIMER'S DISEASE
The case shows the need for psychiatrists to manage end-of-life care for dementia patients, including respecting patients' wishes and using hospice services.
research Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol.
Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.
research Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Risk of valproic acid-related alopecia: A systematic review and meta-analysis
Valproic acid increases the risk of hair loss more than other drugs, especially in migraine patients, and lamotrigine may be a safer alternative.
research 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: A retrospective study
Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.
research 胃切除・腸切除術後の退院指導-パンフレットを使用して-
Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Does Inhibition of Aldose Reductase Contribute to the Anti-Inflammatory Action of Setipiprant?
Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.